Keryx Biopharmaceuticals Inc Announces $55 Million Proposed Public Offering of Common Stock

Keryx Biopharmaceuticals Inc announced that it has commenced a $55 million underwritten public offering of shares of its common stock. In connection with this offering, Keryx expects to grant to the underwriters a 30-day option to purchase additional shares of common stock, equal to up to 15% of the number of shares of common stock sold in the offering. J.P. Morgan is acting as the sole book-running manager in the offering. We intend to use the net proceeds from the sale of our common stock to fund pre-launch/launch inventory build-up and select pre-commercial/commercial activities related to Zerenex, and other general corporate purposes.